VEGF: Potential therapy for renal regeneration

F1000 Medicine Reports

Volumn 4, Issue 1, 2012, Pages

  Chade, Alejandro R ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ARTICLE; CHRONIC DISEASE; KIDNEY INJURY; KIDNEY MICROCIRCULATION; KIDNEY REGENERATION; MICROCIRCULATION; NONHUMAN; REGENERATION; RENAL PROTECTION; RENOVASCULAR DISEASE;

EID: 84856048097     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M4-1     Document Type: Article

References (38)

1. US Renal Data System: USRDS 2010 Annual Data Report; Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes ofHealth,National Institute of Diabetes, and Digestive and Kidney Diseases; 2011. [http://www.usrds.org/atlas10.aspx]
2. Dworkin LD, Murphy T: Is there any reason to stent atherosclerotic renal artery stenosis? Am J Kidney Dis 2010, 56:259-63. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
3. Hansen KJ, Edwards MS, Craven TE, Cherr GS, Jackson SA, Appel RG, Burke GL, Dean RH: Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg 2002, 36:443-51.
4. US Renal Data System: USRDS 2005 Annual Data Report; Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes, and Digestive and Kidney Diseases; 2005. [http://www. usrds.org/atlas05.aspx]
5. Uchimura H, Marumo T, Takase O, Kawachi H, Shimizu F, Hayashi M, Saruta T, Hishikawa K, Fujita T: Intrarenal injection of bone marrow-derived angiogenic cells reduces endothelial injury and mesangial cell activation in experimental glomerulonephritis. J Am Soc Nephrol 2005, 16:997-1004. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
6. Chade AR, Zhu X, Lavi R, Krier JD, Pislaru S, Simari RD, Napoli C, Lerman A, Lerman LO: Endothelial progenitor cells restore renal function in chronic experimental renovascular disease. Circulation 2009, 119:547-57.
7. Ma YY, Sun D, Li J, Yin ZC: Transplantation of endothelial progenitor cells alleviates renal interstitial fibrosis in a mouse model of unilateral ureteral obstruction. Life Sci 2011, 86:798-807. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
8. Goligorsky MS, Kuo MC, Patschan D, Verhaar MC: Review article: endothelial progenitor cells in renal disease. Nephrology (Carlton) 2009, 14:291-7.
9. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S: Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001, 938:36-45. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
10. Zisa D, Shabbir A, Mastri M, Suzuki G, Lee T: Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells. Am J Physiol Regul Integr Comp Physiol 2009, 297:R1503-15. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
11. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-76. (Pubitemid 36749215)
12. Eremina V, Quaggin SE: The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004, 13:9-15. (Pubitemid 39069893)
13. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400. (Pubitemid 38618122)
14. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40. (Pubitemid 43108832)
15. Osada T, Chong G, Tansik R, Hong T, Spector N, Kumar R, Hurwitz HI, Dev I, Nixon AB, Lyerly HK, Clay T, Morse MA: The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008, 57:1115-24.
16. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008, 358:1129-36. Changes Clinical Practice F1000 Factor 11 Evaluated by Alejandro Chade 10 Oct 2008, Ramon Bonegio and David Salant 27 May 2008, Terence H Cook 08 Apr 2008, Andrew Davenport 17 Mar 2008
17. Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96:1788-95. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
18. Krentz AJ, Clough G, Byrne CD: Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes Obes Metab 2007, 9:781-91. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
19. Uzu T, Kida Y, Shirahashi N, Harada T, Yamauchi A, Nomura M, Isshiki K, Araki S, Sugimoto T, Koya D, Haneda M, Kashiwagi A, Kikkawa R: Cerebral microvascular disease predicts renal failure in type 2 diabetes. J Am Soc Nephrol 2010, 21:520-6. F1000 Factor 8 Evaluated by Takahiko Nakagawa 12 Jan 2011, Alejandro Chade 10 Feb 2010
20. Kuo L, Davis MJ, Cannon MS, Chilian WM: Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by L-arginine. Circ Res 1992, 70:465-76. F1000 Factor 6 Evaluated by Alejandro Chade15 Dec 2011
21. Johnson RJ, Rodriguez-Iturbe B, Schreiner GF, Herrera-Acosta J: Hypertension: a microvascular and tubulointerstitial disease. J Hypertens Suppl 2002, 20:S1-7. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
22. Zhu XY, Daghini E, Chade AR, Versari D, Krier JD, Textor KB, Lerman A, Lerman LO: Myocardial microvascular function during acute coronary artery stenosis: effect of hypertension and hypercholesterolaemia. Cardiovasc Res 2009, 83:371-80.
23. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Bonow RO: Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000, 101:118-21. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
24. Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, Losordo DW, Hendel RC, Bonow RO, Eppler SM, Zioncheck TF, Holmgren EB, McCluskey ER: Intracoronary administration of recombinant human vascular endothelialgrowth factor to patients with coronary artery disease. Am Heart J 2001, 142:872-80. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
25. Wafai R, Tudor EM, Angus JA, Wright CE: Vascular effects of FGF-2 and VEGF-B in rabbits with bilateral hind limb ischemia. J Vasc Res 2009, 46:45-54. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
26. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ: Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001, 12:1448-57. F1000 Factor 8 Evaluated by Alejandro Chade 15 Dec 2011
27. Basile DP, Fredrich K, Chelladurai B, Leonard EC, Parrish AR: Renal ischemia reperfusion inhibits VEGF expression and induces ADAMTS-1, a novel VEGF inhibitor. Am J Physiol Renal Physiol 2008, 294:F928-36. F1000 Factor 8 Evaluated by Alejandro Chade 15 Dec 2011
28. Leonard EC, Friedrich JL, Basile DP: VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol Renal Physiol 2008, 295:F1648-57. F1000 Factor 8 Evaluated by Alejandro Chade 15 Dec 2011
29. Chade AR, Kelsen S: Renal microvascular disease determines the responses to revascularization in experimental renovascular disease. Circ Cardiovasc Interv 2010, 3:376-83.
30. Iliescu R, Fernandez SR, Kelsen S, Maric C, Chade AR: Role of renal microcirculation in experimental renovascular disease. Nephrol Dial Transplant 2010, 25:1079-87.
31. Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, Lerman LO: Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. Faseb J 2006, 20:1706-8.
32. Zhu XY, Chade AR, Rodriguez-Porcel M, Bentley MD, Ritman EL, Lerman A, Lerman LO: Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. Arterioscler Thromb Vasc Biol 2004, 24:1854-9 (Pubitemid 39350303)
33. Findley CM, Cudmore MJ, Ahmed A, Kontos CD: VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2007, 27:2619-26. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
34. Chen JX, Stinnett A: Disruption of Ang-1/Tie-2 signaling contributes to the impaired myocardial vascular maturation and angiogenesis in type II diabetic mice. Arterioscler Thromb Vasc Biol 2008, 28:1606-13. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
35. Somanath PR, Chen J, Byzova TV: Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healing. Angiogenesis 2008, 11:277-88. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
36. Saif J, Schwarz TM, Chau DY, Henstock J, Sami P, Leicht SF, Hermann PC, Alcala S, Mulero F, Shakesheff KM, Heeschen C, Aicher A: Combination of injectable multiple growth factor-releasing scaffolds and cell therapy as an advanced modality to enhance tissue neovascularization. Arterioscler Thromb Vasc Biol 2010, 30:1897-1904. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
37. Lu Y, Xiong Y, Huo Y, Han J, Yang X, Zhang R, Zhu DS, Klein-Hessling S, Li J, Zhang X, Han X, Li Y, Shen B, He Y, Shibuya M, Feng GS, Luo J: Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway. Proc Natl Acad Sci U S A 108:2957-62. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011
38. Morita T, Kakinuma Y, Kurabayashi A, Fujieda M, Sato T, Shuin T, Furihata M, Wakiguchi H: Conditional VHL gene deletion activates a local NO-VEGF axis in a balanced manner reinforcing resistance to endothelium-targeted glomerulonephropathy. Nephrol Dial Transplant 2011, 26:4023-31. F1000 Factor 6 Evaluated by Alejandro Chade 15 Dec 2011